CNS Biopharma Merger
Supernus and Indivior Agree to All-Stock Merger, Forming $2.2 Billion CNS Biopharma Powerhouse
Anonymous
Key Points
1
Indivior stockholders will receive 1.5401 Indivior common shares for each Supernus share, and Indivior stockholders are projected to own about 56.5% of the combined company while Supernus holders will own about 43.5%.
2
Pre-market trading reflected investor enthusiasm: Supernus up about 23.24% and Indivior up about 4.97% ahead of the closing, signaling strong market reception to the planned combination.
3
Supernus previously completed a $571 million acquisition of Sage Therapeutics, which added Zurzuvae (zuranolone) for postpartum depression to its CNS portfolio, complementing Indivior’s opioid-use-disorder drugs in the planned merger.
4
The deal is described as a tax-free merger of equals, with the combined company headquartered in Rockville, Maryland, and continuing to trade on Nasdaq as SUPN after the close.
Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to merge in an all-stock deal that would create a central nervous system drug company with about $2.2 billion in annual revenue, according to Reuters and Pharmaphorum. The combined company will keep the Supernus name, trade on Nasdaq under the ticker SUPN, and be headquartered in Rockville, Maryland.
Investors cheered the news. Supernus shares jumped about 23.24% in pre-market trading, while Indivior climbed roughly 4.97%, according to Benzinga. The deal is expected to close in the fourth quarter of 2026, subject to regulatory and shareholder approvals.
How the All-Stock Deal Is Structured
The merger is structured as a tax-free, all-stock transaction. Indivior stockholders will receive 1.5401 Indivior common shares for each Supernus share they hold. At closing, Indivior shareholders will own about 56.5% of the new company, while Supernus shareholders will hold roughly 43.5%, according to Kalkine Media.
Indivior stockholders will also receive a one-time $1 billion cash dividend. That payout will be financed through a $650 million loan facility. Supernus CEO Jack Khattar will lead the merged company. Indivior CEO Tony Kingsley will serve as board chair.
An 11-Drug Portfolio Spanning Psychiatry and Addiction
The combined company will have 11 marketed medicines spanning psychiatry, neurology, and addiction treatment, according to Reuters. Indivior brings its flagship opioid-use-disorder drugs, including Suboxone. Supernus adds treatments like Oxtellar XR and Trokendi XR for epilepsy.
Supernus also recently added Zurzuvae, a drug for postpartum depression, after it completed a $571 million acquisition of Sage Therapeutics. That drug now sits alongside Indivior's addiction medicines in the planned combined portfolio, according to Yahoo Finance.
$125 Million in Savings and Nearly $900 Million in EBITDA
The two companies expect to cut costs by about $125 million per year once the deal closes. On a combined basis, the new Supernus would generate pro forma EBITDA — a measure of operating profit — of roughly $888 million, according to Pharmaphorum.
Executives say the stronger cash flow will let the company pursue further acquisitions after the merger closes. The deal's structure as a merger of equals means neither side paid a traditional acquisition premium, which helps preserve capital for future deals.
What Comes Next Before the Deal Closes
The merger still needs approval from shareholders of both companies, plus sign-off from regulators. The deal is expected to close in Q4 2026, according to Kalkine Media. Both boards have already approved the transaction.
Once complete, the new Supernus will be one of the larger pure-play CNS drug companies in the United States. With $2.2 billion in annual revenue and a broad drug portfolio, it will be positioned to compete for deals in a crowded neuroscience market, according to Benzinga.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
19
Articles
75
Reach
94
A
AnonymousAuthor